Abstract
The pharmacokinetics and toxicity of two schedules of etoposide administration were studied in 19 patients suffering from metastatic non-small-cell lung cancer. Ten subjects received a 72-h continuous venous infusion (CVI) of 360 mg/m2 etoposide, and nine were given a daily dose of 120 mg/m2 for 3 consecutive days. In the two groups 80 mg/m2 cis-diamminedichloroplatinum (II) (CDDP) was infused on day 1. With CVI, the steady-state plasma concentration was reached 12-24 h after the start of the treatment. The plasma elimination rate showed a biexponential decay curve in both groups. No significant difference between total body clearance and the beta-phase volume of distribution was noted between the two modalities of administration. No relationship was found between biological and pharmacokinetic parameters.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Carcinoma, Non-Small-Cell Lung / blood
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Cisplatin / administration & dosage
-
Cisplatin / adverse effects
-
Drug Administration Schedule
-
Drug Evaluation
-
Etoposide / administration & dosage
-
Etoposide / adverse effects
-
Etoposide / pharmacokinetics*
-
Female
-
Humans
-
Infusions, Intravenous / methods
-
Leukopenia / chemically induced
-
Lung Neoplasms / blood
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / pathology
-
Male
-
Metabolic Clearance Rate
-
Middle Aged
-
Neoplasm Metastasis
-
Remission Induction
-
Thrombocytopenia / chemically induced